The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region.The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.本發明係相關於一種新穎抗體，能特異性地結合至人類c-Met受體，及/或能特異性地抑制該受體之酪胺酸激酶活性，並具增進之拮抗活性，該抗體包含有一經修飾之樞紐區域。本發明亦相關於一種組成物，包含有此一與c-Met拮抗之抗體，以及其作為癌症治療藥物之用途。
